<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34997582</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5381</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>179</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of pharmacology</Title>
          <ISOAbbreviation>Br J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>5-HT<sub>3</sub> <sub>A</sub> receptors maintain hippocampal LTP in a CB<sub>1</sub> and GABA<sub>A</sub> receptor- dependent manner for spatial memory.</ArticleTitle>
        <Pagination>
          <StartPage>2969</StartPage>
          <EndPage>2985</EndPage>
          <MedlinePgn>2969-2985</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15793</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">As the only ionotropic receptor in the 5-HT receptor family, the 5-HT<sub>3</sub> receptor (5-HT<sub>3</sub> R) is involved in psychiatric disorders and its modulators have potential therapeutic effects for cognitive impairment in these disorders. However, it remains unclear how 5-HT<sub>3</sub> Rs shape synaptic plasticity for memory function.</AbstractText>
          <AbstractText Label="EXPERIMENTAL APPROACH" NlmCategory="METHODS">Extracellular as well as whole-cell electrophysiological recordings were used to monitor hippocampal LTP and synaptic transmission in hippocampal slices in 5-HT<sub>3</sub> AR knockout or 5-HT<sub>3</sub> AR-GFP mice. Immunocytochemistry, qRT-PCR and western blotting were used to measure receptor expression. We also assessed hippocampal dependent cognition and memory, using the Morris water maze (MWM) and novel object recognition.</AbstractText>
          <AbstractText Label="KEY RESULTS" NlmCategory="RESULTS">We found that 5-HT<sub>3</sub> R dysfunction impaired hippocampal LTP in Schaffer collateral (SC)-CA1 pathway in hippocampal slices, by facilitating GABAergic inputs in pyramidal cells. This effect was dependent on 5-HT<sub>3</sub> Rs on axon terminals. It resulted from reduced expression and function of the cannabinoid receptor 1 (CB<sub>1</sub> R) co-localized with 5-HT<sub>3</sub> Rs on axon terminals, and then led to diminishment of tonic inhibition of GABA release by CB<sub>1</sub> Rs. Inhibition of CB<sub>1</sub> Rs mimicked the facilitation of GABAergic transmission by 5-HT<sub>3</sub> R disruption. Consequently, mice with hippocampal 5-HT<sub>3</sub> R disruption exhibited impaired spatial memory in MWM tasks.</AbstractText>
          <AbstractText Label="CONCLUSION AND IMPLICATIONS" NlmCategory="CONCLUSIONS">These results suggest that 5-HT<sub>3</sub> Rs are crucial in enabling hippocampal synaptic plasticity via a novel CB<sub>1</sub> R-GABA<sub>A</sub> -dependent pathway to regulate spatial memory.</AbstractText>
          <CopyrightInformation>© 2022 The British Pharmacological Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jing-Jing</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Xiao-Qian</ForeName>
            <Initials>XQ</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Zi-Ying</ForeName>
            <Initials>ZY</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Dong-Qing</ForeName>
            <Initials>DQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, York University, Toronto, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Qiu-Chen</ForeName>
            <Initials>QC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Mu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Research and Development, CNS, GeneScience Pharmaceuticals Co., Ltd, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Zhi-Li</ForeName>
            <Initials>ZL</Initials>
            <Identifier Source="ORCID">0000-0001-9359-1150</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Ling-Jing</ForeName>
            <Initials>LJ</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hui-Hui</ForeName>
            <Initials>HH</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Ning</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, York University, Toronto, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yung</LastName>
            <ForeName>Wing-Ho</ForeName>
            <Initials>WH</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Ministry of Education), Department of Physiology and Pharmacology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biology, York University, Toronto, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Pharmacol</MedlineTA>
        <NlmUniqueID>7502536</NlmUniqueID>
        <ISSNLinking>0007-1188</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043884">Receptor, Cannabinoid, CB1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>333DO1RDJY</RegistryNumber>
          <NameOfSubstance UI="D012701">Serotonin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>56-12-2</RegistryNumber>
          <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017774" MajorTopicYN="Y">Long-Term Potentiation</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043884" MajorTopicYN="N">Receptor, Cannabinoid, CB1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065852" MajorTopicYN="Y">Spatial Memory</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">5-HT3R</Keyword>
        <Keyword MajorTopicYN="N">CB1R</Keyword>
        <Keyword MajorTopicYN="N">GABA</Keyword>
        <Keyword MajorTopicYN="N">spatial memory</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34997582</ArticleId>
        <ArticleId IdType="doi">10.1111/bph.15793</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Akhondzadeh, S., Mohammadi, N., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Jamshidi, A. H., &amp; Forghani, S. (2009). Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. Schizophrenia Research, 107(2-3), 206-212. https://doi.org/10.1016/j.schres.2008.08.004</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander, S. P. H., Christopoulos, A., Davenport, A.P., Kelly, E., Mathie, A., Peters, J.A., Veale, E.L., Armstrong, J.F., Faccenda, E., Harding, S.D., Pawson, A.J., Sharman, J.L., Southan, C., Davies,, J.A., &amp; Collaborators, C. G. T. P. (2019). The concise guide to pharmacology 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176(S1), S21-S141. https://doi.org/10.1111/bph.14748</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., &amp; Sharman, J. L. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176(S1), S297-S396. https://doi.org/10.1111/bph.14751</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., &amp; Kelly, E. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology, 176(S1), S142-S228. https://doi.org/10.1111/bph.14750</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Mangum, J., Wonnacott, S., &amp; Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British Journal of Pharmacology, 175(3), 407-411. https://doi.org/10.1111/bph.14112</Citation>
        </Reference>
        <Reference>
          <Citation>Austin, M. P., Mitchell, P., &amp; Goodwin, G. M. (2001). Cognitive deficits in depression: Possible implications for functional neuropathology. The British Journal of Psychiatry: The Journal of Mental Science, 178, 200-206. https://doi.org/10.1192/bjp.178.3.200</Citation>
        </Reference>
        <Reference>
          <Citation>Barnes, J. M., Costall, B., Coughlan, J., Domeney, A. M., Gerrard, P. A., Kelly, M. E., Naylor, R. J., Onaivi, E. S., Tomkins, D. M., &amp; Tyers, M. B. (1990). The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacology, Biochemistry, and Behavior, 35(4), 955-962. https://doi.org/10.1016/0091-3057(90)90385-U</Citation>
        </Reference>
        <Reference>
          <Citation>Barnes, N. M., &amp; Sharp, T. (1999). A review of central 5-HT receptors and their function. Neuropharmacology, 38(8), 1083-1152. https://doi.org/10.1016/S0028-3908(99)00010-6</Citation>
        </Reference>
        <Reference>
          <Citation>Baumgarten, H. G., &amp; Grozdanovic, Z. (1995). Psychopharmacology of central serotonergic systems. Pharmacopsychiatry, 28(Suppl 2), 73-79. https://doi.org/10.1055/s-2007-979623</Citation>
        </Reference>
        <Reference>
          <Citation>Betry, C., Etievant, A., Pehrson, A., Sanchez, C., &amp; Haddjeri, N. (2015). Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry, 58, 38-46. https://doi.org/10.1016/j.pnpbp.2014.12.002</Citation>
        </Reference>
        <Reference>
          <Citation>Bhatnagar, S., Nowak, N., Babich, L., &amp; Bok, L. (2004). Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behavioural Brain Research, 153(2), 527-535. https://doi.org/10.1016/j.bbr.2004.01.018</Citation>
        </Reference>
        <Reference>
          <Citation>Black, M. D., Stevens, R. J., Rogacki, N., Featherstone, R. E., Senyah, Y., Giardino, O., Borowsky, B., Stemmelin, J., Cohen, C., Pichat, P., &amp; Arad, M. (2011). AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: Improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology, 215(1), 149-163. https://doi.org/10.1007/s00213-010-2124-0</Citation>
        </Reference>
        <Reference>
          <Citation>Chevaleyre, V., &amp; Piskorowski, R. (2014). Modulating excitation through plasticity at inhibitory synapses. Frontiers in Cellular Neuroscience, 8, 1-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Chu, A., &amp; Wadhwa, R. (2020). Selective serotonin reuptake inhibitors. StatPearls [Internet]. StatPearls Publishing.</Citation>
        </Reference>
        <Reference>
          <Citation>Cooper, Z. D., &amp; Craft, R. M. (2018). Sex-dependent effects of cannabis and cannabinoids: A translational perspective. Neuropsychopharmacology, 43(1), 34-51. https://doi.org/10.1038/npp.2017.140</Citation>
        </Reference>
        <Reference>
          <Citation>Cruzat, A., Gonzalez-Andrades, M., Mauris, J., AbuSamra, D. B., Chidambaram, P., Kenyon, K. R., Chodosh, J., Dohlman, C. H., &amp; Argüeso, P. (2018). Colocalization of Galectin-3 with CD147 is associated with increased gelatinolytic activity in ulcerating human corneas. Investigative Ophthalmology &amp; Visual Science, 9(1), 223-230.</Citation>
        </Reference>
        <Reference>
          <Citation>Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., &amp; MacEwan, D. J. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology, 175(7), 987-993. https://doi.org/10.1111/bph.14153</Citation>
        </Reference>
        <Reference>
          <Citation>Derkach, V., Surprenant, A., &amp; North, R. A. (1989). 5-HT3 receptors are membrane ion channels. Nature, 339(6227), 706-709. https://doi.org/10.1038/339706a0</Citation>
        </Reference>
        <Reference>
          <Citation>Dorostkar, M. M., &amp; Boehm, S. (2007). Opposite effects of presynaptic 5-HT3 receptor activation on spontaneous and action potential-evoked GABA release at hippocampal synapses. Journal of Neurochemistry, 100(2), 395-405. https://doi.org/10.1111/j.1471-4159.2006.04218.x</Citation>
        </Reference>
        <Reference>
          <Citation>Dudok, B., Barna, L., Ledri, M., Szabo, S. I., Szabadits, E., Pinter, B., Woodhams, S. G., Henstridge, C. M., Balla, G. Y., Nyilas, R., &amp; Varga, C. (2015). Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nature Neuroscience, 18(1), 75-86. https://doi.org/10.1038/nn.3892</Citation>
        </Reference>
        <Reference>
          <Citation>Ferezou, I., Cauli, B., Hill, E. L., Rossier, J., Hamel, E., &amp; Lambolez, B. (2002). 5-HT3 receptors mediate serotonergic fast synaptic excitation of neocortical vasoactive intestinal peptide/cholecystokinin interneurons. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 22(17), 7389-7397. https://doi.org/10.1523/JNEUROSCI.22-17-07389.2002</Citation>
        </Reference>
        <Reference>
          <Citation>Ferguson, K. A., &amp; Cardin, J. A. (2020). Mechanisms underlying gain modulation in the cortex. Nature Reviews Neuroscience, 21(2), 80-92.</Citation>
        </Reference>
        <Reference>
          <Citation>Fishell, G., &amp; Rudy, B. (2011). Mechanisms of inhibition within the telencephalon: “Where the wild things are”. Annual Review of Neuroscience, 34, 535-567. https://doi.org/10.1146/annurev-neuro-061010-113717</Citation>
        </Reference>
        <Reference>
          <Citation>Freund, T. F., &amp; Katona, I. (2007). Perisomatic inhibition. Neuron, 56(1), 33-42. https://doi.org/10.1016/j.neuron.2007.09.012</Citation>
        </Reference>
        <Reference>
          <Citation>Fukushima, T., Ohtsubo, T., Tsuda, M., Yanagawa, Y., &amp; Hori, Y. (2009). Facilitatory actions of serotonin type 3 receptors on GABAergic inhibitory synaptic transmission in the spinal superficial dorsal horn. Journal of Neurophysiology, 102(3), 1459-1471. https://doi.org/10.1152/jn.91160.2008</Citation>
        </Reference>
        <Reference>
          <Citation>Glickfeld, L. L., Atallah, B. V., &amp; Scanziani, M. (2008). Complementary modulation of somatic inhibition by opioids and cannabinoids. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 28(8), 1824-1832. https://doi.org/10.1523/JNEUROSCI.4700-07.2008</Citation>
        </Reference>
        <Reference>
          <Citation>Gothert, M. (2013). Serotonin discovery and stepwise disclosure of 5-HT receptor complexity over four decades. Part I. General background and discovery of serotonin as a basis for 5-HT receptor identification. Pharmacological Reports, 65(4), 771-786. https://doi.org/10.1016/S1734-1140(13)71059-4</Citation>
        </Reference>
        <Reference>
          <Citation>Gothert, M., Bonisch, H., Malinowska, B., &amp; Schlicker, E. (2020). Serotonin discovery and stepwise disclosure of 5-HT receptor complexity over four decades. Part II. Some contributions of Manfred Gothert. Pharmacological Reports, 72, 271-284. https://doi.org/10.1007/s43440-019-00047-4</Citation>
        </Reference>
        <Reference>
          <Citation>Hargreaves, A. C., Lummis, S. C., &amp; Taylor, C. W. (1994). Ca2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors. Molecular Pharmacology, 46(6), 1120-1128.</Citation>
        </Reference>
        <Reference>
          <Citation>Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., &amp; Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America, 87(5), 1932-1936. https://doi.org/10.1073/pnas.87.5.1932</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffman, A. F., &amp; Lupica, C. R. (2000). Mechanisms of cannabinoid inhibition of GABAA synaptic transmission in the hippocampus. The Journal of Neuroscience, 20(7), 2470-2479. https://doi.org/10.1523/JNEUROSCI.20-07-02470.2000</Citation>
        </Reference>
        <Reference>
          <Citation>Howlett, A. C. (2005). Cannabinoid receptor signaling. Handbook of Experimental Pharmacology, 168, 53-79. https://doi.org/10.1007/3-540-26573-2_2</Citation>
        </Reference>
        <Reference>
          <Citation>Huang, Y., Yoon, K., Ko, H., Jiao, S., Ito, W., Wu, J. Y., Yung, W. H., Lu, B., &amp; Morozov, A. (2016). 5-HT3a receptors modulate hippocampal gamma oscillations by regulating synchrony of parvalbumin-positive interneurons. Cerebral Cortex, 26(2), 576-585. https://doi.org/10.1093/cercor/bhu209</Citation>
        </Reference>
        <Reference>
          <Citation>Keimpema, E., Straiker, A., Mackie, K., Harkany, T., &amp; Hjerling-Leffler, J. (2012). Sticking out of the crowd: The molecular identity and development of cholecystokinin-containing basket cells. The Journal of Physiology, 590(4), 703-714. https://doi.org/10.1113/jphysiol.2011.224386</Citation>
        </Reference>
        <Reference>
          <Citation>Kelley, S. P., Bratt, A. M., &amp; Hodge, C. W. (2003). Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice. European Journal of Pharmacology, 461(1), 19-25. https://doi.org/10.1016/S0014-2999(02)02960-6</Citation>
        </Reference>
        <Reference>
          <Citation>Kim, D. D., Barr, A. M., Honer, W. G., &amp; Procyshyn, R. M. (2018). Exercise-induced hippocampal neurogenesis: 5-HT3 receptor antagonism by antipsychotics as a potential limiting factor in Schizophrenia. Molecular Psychiatry, 23(12), 2252-2253. https://doi.org/10.1038/s41380-018-0022-8</Citation>
        </Reference>
        <Reference>
          <Citation>Kondo, M., Nakamura, Y., Ishida, Y., &amp; Shimada, S. (2015). The 5-HT3 receptor is essential for exercise-induced hippocampal neurogenesis and antidepressant effects. Molecular Psychiatry, 20(11), 1428-1437. https://doi.org/10.1038/mp.2014.153</Citation>
        </Reference>
        <Reference>
          <Citation>Koyama, S., Matsumoto, N., Kubo, C., &amp; Akaike, N. (2000). Presynaptic 5-HT3 receptor-mediated modulation of synaptic GABA release in the mechanically dissociated rat amygdala neurons. The Journal of Physiology, 529(Pt 2), 373-383. https://doi.org/10.1111/j.1469-7793.2000.00373.x</Citation>
        </Reference>
        <Reference>
          <Citation>Lee, R. S., Hermens, D. F., Porter, M. A., &amp; Redoblado-Hodge, M. A. (2012). A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. Journal of Affective Disorders, 140(2), 113-124. https://doi.org/10.1016/j.jad.2011.10.023</Citation>
        </Reference>
        <Reference>
          <Citation>Leger, M., Quiedeville, A., Bouet, V., Haelewyn, B., Boulouard, M., Schumann-Bard, P., &amp; Freret, T. (2013). Object recognition test in mice. Nature Protocols, 8(12), 2531-2537. https://doi.org/10.1038/nprot.2013.155</Citation>
        </Reference>
        <Reference>
          <Citation>Leiser, S. C., Li, Y., Pehrson, A. L., Dale, E., Smagin, G., &amp; Sanchez, C. (2015). Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: A review of individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine. ACS Chemical Neuroscience, 6(7), 970-986. https://doi.org/10.1021/cn500340j</Citation>
        </Reference>
        <Reference>
          <Citation>Lenz, R. A., &amp; Alger, B. E. (1999). Calcium dependence of depolarization-induced suppression of inhibition in rat hippocampal CA1 pyramidal neurons. Journal of Physiology, 521(Pt 1), 147-157.</Citation>
        </Reference>
        <Reference>
          <Citation>Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., &amp; Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177(16), 3611-3616. https://doi.org/10.1111/bph.15178</Citation>
        </Reference>
        <Reference>
          <Citation>Lovinger, D. M. (2008). Presynaptic modulation by endocannabinoids. Handbook of Experimental Pharmacology, 184, 435-477. https://doi.org/10.1007/978-3-540-74805-2_14</Citation>
        </Reference>
        <Reference>
          <Citation>Manders, E. M. M., Verbeek, F. J., &amp; Aten, J. A. (1993). Measurement of co-localization of objects in dual-colour confocal images. Journal of Microscopy, 169(3), 375-382.</Citation>
        </Reference>
        <Reference>
          <Citation>Marsicano, G., &amp; Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. The European Journal of Neuroscience, 11(12), 4213-4225. https://doi.org/10.1046/j.1460-9568.1999.00847.x</Citation>
        </Reference>
        <Reference>
          <Citation>Meredith, R. M., Floyer-Lea, A. M., &amp; Paulsen, O. (2003). Maturation of long-term potentiation induction rules in rodent hippocampus: Role of GABAergic inhibition. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 23(35), 11142-11146. https://doi.org/10.1523/JNEUROSCI.23-35-11142.2003</Citation>
        </Reference>
        <Reference>
          <Citation>Miquel, M. C., Emerit, M. B., Nosjean, A., Simon, A., Rumajogee, P., Brisorgueil, M. J., Doucet, E., Hamon, M., &amp; Verge, D. (2002). Differential subcellular localization of the 5-HT3-As receptor subunit in the rat central nervous system. The European Journal of Neuroscience, 15(3), 449-457. https://doi.org/10.1046/j.0953-816x.2001.01872.x</Citation>
        </Reference>
        <Reference>
          <Citation>Morales, M., &amp; Backman, C. (2002). Coexistence of serotonin 3 (5-HT3) and CB1 cannabinoid receptors in interneurons of hippocampus and dentate gyrus. Hippocampus, 12(6), 756-764. https://doi.org/10.1002/hipo.10025</Citation>
        </Reference>
        <Reference>
          <Citation>Naghdi, N., &amp; Harooni, H. E. (2005). The effect of intrahippocampal injections of ritanserin (5HT2A/2C antagonist) and granisetron (5HT3 antagonist) on learning as assessed in the spatial version of the water maze. Behavioural Brain Research, 157(2), 205-210. https://doi.org/10.1016/j.bbr.2004.06.024</Citation>
        </Reference>
        <Reference>
          <Citation>Németh, B., Ledent, C., Freund, T. F., &amp; Hájos, N. (2008). CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2. Neuropharmacology, 54(1), 51-57. https://doi.org/10.1016/j.neuropharm.2007.07.003</Citation>
        </Reference>
        <Reference>
          <Citation>Okada, M., Okubo, R., &amp; Fukuyama, K. (2019). Vortioxetine subchronically activates serotonergic transmission via desensitization of serotonin 5-HT1A receptor with 5-HT3 receptor inhibition in rats. International Journal of Molecular Sciences, 20(24), 6235-6252. https://doi.org/10.3390/ijms20246235</Citation>
        </Reference>
        <Reference>
          <Citation>Park, S. M., &amp; Williams, C. L. (2012). Contribution of serotonin type 3 receptors in the successful extinction of cued or contextual fear conditioned responses: Interactions with GABAergic signaling. Reviews in the Neurosciences, 23(5-6), 555-569.</Citation>
        </Reference>
        <Reference>
          <Citation>Paudice, P., &amp; Raiteri, M. (1991). Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. British Journal of Pharmacology, 103(3), 1790-1794. https://doi.org/10.1111/j.1476-5381.1991.tb09864.x</Citation>
        </Reference>
        <Reference>
          <Citation>Pehrson, A. L., &amp; Sanchez, C. (2014). Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums, 19(2), 121-133. https://doi.org/10.1017/S1092852913000540</Citation>
        </Reference>
        <Reference>
          <Citation>Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410</Citation>
        </Reference>
        <Reference>
          <Citation>Rammes, G., Eisensamer, B., Ferrari, U., Shapa, M., Gimpl, G., Gilling, K., Parsons, C., Riering, K., Hapfelmeier, G., Bondy, B., &amp; Zieglgänsberger, W. (2004). Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Molecular Psychiatry, 9(9), 846-858. https://doi.org/10.1038/sj.mp.4001490</Citation>
        </Reference>
        <Reference>
          <Citation>Ronde, P., &amp; Nichols, R. A. (1998). High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum. Journal of Neurochemistry, 70(3), 1094-1103.</Citation>
        </Reference>
        <Reference>
          <Citation>Rozzini, L., Chilovi, B. V., Conti, M., Bertoletti, E., Zanetti, M., Trabucchi, M., &amp; Padovani, A. (2010). Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. International Psychogeriatrics, 22(1), 114-119. https://doi.org/10.1017/S1041610209990184</Citation>
        </Reference>
        <Reference>
          <Citation>Rubino, T., Zamberletti, E., &amp; Parolaro, D. (2015). Endocannabinoids and mental disorders. Handbook of Experimental Pharmacology, 231, 261-283. https://doi.org/10.1007/978-3-319-20825-1_9</Citation>
        </Reference>
        <Reference>
          <Citation>Sanchez, C., Asin, K. E., &amp; Artigas, F. (2015). Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology &amp; Therapeutics, 145, 43-57. https://doi.org/10.1016/j.pharmthera.2014.07.001</Citation>
        </Reference>
        <Reference>
          <Citation>Stahl, S. M. (2010). Enhancing outcomes from major depression: Using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectrums, 15(2), 79-94. https://doi.org/10.1017/S1092852900027334</Citation>
        </Reference>
        <Reference>
          <Citation>Sudweeks, S. N., Hooft, J. A., &amp; Yakel, J. L. (2002). Serotonin 5-HT3 receptors in rat CA1 hippocampal interneurons: Functional and molecular characterization. The Journal of Physiology, 544(3), 715-726. https://doi.org/10.1113/jphysiol.2002.029736</Citation>
        </Reference>
        <Reference>
          <Citation>Takacs, V. T., Szonyi, A., Freund, T. F., Nyiri, G., &amp; Gulyas, A. I. (2015). Quantitative ultrastructural analysis of basket and axo-axonic cell terminals in the mouse hippocampus. Brain Structure &amp; Function, 220(2), 919-940. https://doi.org/10.1007/s00429-013-0692-6</Citation>
        </Reference>
        <Reference>
          <Citation>Teissier, A., Soiza-Reilly, M., &amp; Gaspar, P. (2017). Refining the role of 5-HT in postnatal development of brain circuits. Frontiers in Cellular Neuroscience, 11, 139-147. https://doi.org/10.3389/fncel.2017.00139</Citation>
        </Reference>
        <Reference>
          <Citation>Varga, V., Losonczy, A., Zemelman, B. V., Borhegyi, Z., Nyiri, G., Domonkos, A., Hangya, B., Holderith, N., Magee, J. C., &amp; Freund, T. F. (2009). Fast synaptic subcortical control of hippocampal circuits. Science, 326(5951), 449-453. https://doi.org/10.1126/science.1178307</Citation>
        </Reference>
        <Reference>
          <Citation>Wilson, R. I., Kunos, G., &amp; Nicoll, R. A. (2001). Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron, 31(3), 453-462. https://doi.org/10.1016/S0896-6273(01)00372-5</Citation>
        </Reference>
        <Reference>
          <Citation>Xu, Y. Y., He, Q., Wang, M. Q., Wang, X., Gong, F. L., Bai, L., Zhang, J., &amp; Wang, W. (2019). Quantifying blood-brain-barrier leakage using a combination of evans blue and high molecular weight FITC-Dextran[J]. Journal of Neuroscience Methods, 325, 108349.</Citation>
        </Reference>
        <Reference>
          <Citation>Zeitz, K. P., Guy, N., Malmberg, A. B., Dirajlal, S., Martin, W. J., Sun, L., Bonhaus, D. W., Stucky, C. L., Julius, D., &amp; Basbaum, A. I. (2002). The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 22(3), 1010-1019. https://doi.org/10.1523/JNEUROSCI.22-03-01010.2002</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang, Z. J., Kang, W. H., Li, Q., Wang, X. Y., Yao, S. M., &amp; Ma, A. Q. (2006). Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study. Schizophrenia Research, 88(1-3), 102-110. https://doi.org/10.1016/j.schres.2006.07.010</Citation>
        </Reference>
        <Reference>
          <Citation>Zou, S., &amp; Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. International Journal of Molecular Sciences, 19(3), 833-855. https://doi.org/10.3390/ijms19030833</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
